Reflections and Major Developments in CLL from ASH 2011

Published on

Topics include: Treatment

Dr. Michael Keating, President of the CLL Global Research Foundation, gives an overview--and his very positive perspective--about the landscape for CLL, including research around Chimeric Antigen Receptors (CAR), Tyrosine Kinase Inhibitors (TKIs), feeding cells, genetic mutations and novel agents in trials.  Look for in-depth interviews from other CLL Global Alliance researchers on these topics coming soon.

View more programs featuring

Produced in association with

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor.  Please have this discussion with your own doctor, that’s how you’ll get care that’s most appropriate for you.


Dr. Keating, you're excited about where we are now? 

So we're beginning to carve out subsets, and this happened in acute leukemia where we found out that there was particular genetics that predicted which drugs would work, so we're at that point now.  We're getting the direction so we can frame our clinical trials very specifically to ask pointed questions.


Page last updated on November 20, 2013